Stockscreener 앱 받기
27.78
0.47%
0.13
시장 영업 전:
27.63
-0.15
-0.54%
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Kiniksa Pharmaceuticals: Making Steady Progress (NASDAQ:KNSA) - Seeking Alpha
Insider’s View: Deciphering Kiniksa Pharmaceuticals International Plc (KNSA)’s Financial Health Through Ratios - DWinneX
How should investors view Kiniksa Pharmaceuticals International Plc (KNSA)? - uspostnews.com
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,265,339, According to a Recent SEC Filing - marketscreener.com
Kiniksa Pharmaceuticals Executives Sell Shares - TradingView
Wall Street analysts’ outlook for Kiniksa Pharmaceuticals International Plc (KNSA) - Sete News
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2025 Earnings Call Transcript - Insider Monkey
3 Stocks Including Kiniksa Pharmaceuticals International That May Be Priced Below Intrinsic Value Estimates - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025: Everyt - GuruFocus
Examining the Potential Price Growth of Kiniksa Pharmaceuticals International Plc (KNSA) - knoxdaily.com
Kiniksa (KNSA) Partners with Carly Pearce for Health Awareness C - GuruFocus
Kiniksa Pharmaceuticals International Plc (KNSA) Stock: A Year of Decreases and Increases - investchronicle.com
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis - GlobeNewswire
Country Star Carly Pearce Opens Up About 4-Year Struggle With Rare Heart Disease in New Campaign - Stock Titan
An Intrinsic Calculation For Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Suggests It's 41% Undervalued - Yahoo Finance
Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance - MSN
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus
Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $36 From $34, Maintains Outperform Rating - marketscreener.com
Kiniksa Pharmaceuticals: A Biotech Stock on the Rise, But What’s Next? - RagingBull
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Kiniksa Pharmaceuticals Surpasses Q1 2025 Revenue Estimates with $137.8 Million, EPS Details Unavailable - GuruFocus
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Res - GuruFocus
Kiniksa Pharmaceuticals Swings to Q1 Net Income, Revenue Increases - marketscreener.com
KNSA: Kiniksa Forecasts Increased ARCALYST Revenue for 2025 | KN - GuruFocus
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution - The Manila Times
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results - TradingView
Kiniksa Q1 Earnings: ARCALYST Revenue Soars 75% to $138M, 2025 Guidance Boosted to $605M - Stock Titan
Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook - Benzinga
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals Sets Q1 2025 Earnings Call Date: How to Access Live Results and Portfolio Updates - Stock Titan
Its Stock Has Paid Off Big Time For Kiniksa Pharmaceuticals International Plc - Sete News
Kiniksa Pharmaceuticals introduces new incentive plan By Investing.com - Investing.com India
Kiniksa Pharmaceuticals introduces new incentive plan - Investing.com Australia
Kiniksa Pharmaceuticals chief commercial officer sells $370,475 in stock By Investing.com - Investing.com South Africa
Kiniksa Pharmaceuticals chief commercial officer sells $370,475 in stock - Investing.com Australia
Lacklustre Performance Is Driving Kiniksa Pharmaceuticals International, plc's (NASDAQ:KNSA) Low P/S - simplywall.st
SEC Form DEFA14A filed by Kiniksa Pharmaceuticals International plc - Quantisnow
Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) PT at $37.17 - Defense World
KNSA Stock Sees Decline of Approximately -1.89% in Last Five Days - knoxdaily.com
Kiniksa CFO Mark Ragosa sells shares worth $368,465 By Investing.com - Investing.com South Africa
Kiniksa CFO Mark Ragosa sells shares worth $368,465 - Investing.com India
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Down 1.8 - GuruFocus
Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock By Investing.com - Investing.com South Africa
Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock - Investing.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Buy Rating from Analysts at Citigroup - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna Sells 9,051 Shares - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Average Target Price from Analysts - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells $809,277.00 in Stock - MarketBeat
Globeflex Capital L P Boosts Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Sells 17,118 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):